Zacharie Kashongwe

Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries

Arnaud Trébucq, V Schwoebel, Zacharie Kashongwe et al. · The International Journal of Tuberculosis and Lung Disease · 2017 · 167 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Childhood Tuberculosis in a Sub-Saharan Tertiary Facility: Epidemiology and Factors Associated with Treatment Outcome

Loukia Aketi, Zacharie Kashongwe, Christian Kinsiona et al. · PLoS ONE · 2016 · 46 citations · Full text

Public Health, Child Health, Infectious Diseases +17

Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries

Arnaud Trébucq, Zacharie Kashongwe, A.S. Bakayoko et al. · EClinicalMedicine · 2020 · 34 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF–identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study

Andre Nyandwe Hamama Bulabula, Jenna Nelson, Eric Mulume Musafiri et al. · Clinical Infectious Diseases · 2018 · 26 citations · Full text

Public Health, Infectious Disease Control, Infectious Diseases +17

Xpert <i>My</i> <i>cobacterium tuberculosis</i>/Rifampicin–Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications

Bertin C Bisimwa, Jean B. Nachega, Robin M. Warren et al. · Clinical Infectious Diseases · 2020 · 22 citations · Full text

Public Health, Infectious Diseases, Antimicrobial Resistance +16